Table 2. Correlation of CIMT with demographic and clinical disease variables in psoriatic arthritis patients.
| Variables | r | p Value |
|---|---|---|
| Age | −0.321 | 0.21 |
| Disease duration | 0.234 | 0.35 |
| DAS 28 | 0.381 | 0.18 |
| DAPSA | 0.345 | 0.16 |
| ESR (mm 1st h) | 0.228 | 0.20 |
| CRP (mg/dL) | 0.304 | 0.10 |
| TC (mg/dL) | 0.210 | 0.23 |
| HDL (mg/dL) | -0.502 | 0.01a |
| LDL (mg/dL) | 0.251 | 0.14 |
| IL-1 (pg/mL) | 0.184 | 0.28 |
| IL-6 (pg/mL) | 0.417 | 0.04a |
| TNF-α (pg/mL) | 0.374 | 0.11 |
| ICAM-1 (ng/mL) | 0.481 | 0.01a |
| VCAM-1 (ng/mL) | 0.284 | 0.17 |
| EPC% | 0.443 | 0.02a |
| FMD% | 0.512 | 0.01a |
Abbreviations: CIMT, carotid intima-media thickness; CRP, C-reactive protein; DAS28, disease activity score of 28 joints; DAPSA, disease activity in psoriatic arthritis; EPCs, endothelial progenitor cells; ESR, erythrocyte sedimentation rate; FMD, flow-mediated dilation; HDL, high-density lipoprotein; ICAM-1, intracellular adhesion molecule 1; IL-1, interleukin-1; IL-6, interleukin-6; LDL, low-density lipoprotein; TC, total cholesterol; TNF-α, tumor necrosis factor-α; VCAM-1, vascular cell adhesion molecule 1.
a
Statiscally significant p < 0.05.